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The aim of this study is to evaluate the medication knowledge achieved by conventional verbal education and the influence
of drug information leaflets in patients with epilepsy. Drug compliance and sources of information of the patients were also
examined.
Fifty-one adults in an epilepsy outpatient clinic participated this survey. These patients were asked to complete a questionnaire
and to specify sources of drug information. Serum drug levels were checked and compared with the self-reported compliance.
Then, drug information leaflets were given to patients. In the next follow-up visit, patients were asked to fill out the same
questionnaire again.
In the baseline assessment, 36 patients (70.6%) could accurately list their medications. However, half of patients were not
knowledgeable about side effects and did not keep a seizure diary. After provision of drug leaflets, the epilepsy medication
assessment score increased from 3.9± 1.9 to 5.1± 1.7 (P < 0.001). In addition, patients reported being compliant most of the
time and this matched drug levels. On average, each patient had 2.8 sources of information and 5 patients used Internet as a tool.
Despite achieving good compliance, conventional verbal education did not sufficiently cover drug-related issues. Providing
patients with written information apparently increase their medication knowledge and probably enhance seizure control.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
Key words: epilepsy; medication education; compliance; antiepileptic drugs; serum drug levels.
INTRODUCTION
Like other chronic illnesses, antiepileptic drug (AED)
therapy in patients with epilepsy is a continuously
balancing process between disease control and side
effects. Drug-related adverse events are well known
to be one of the leading causes of treatment dis-
continuation by patients themselves. In the treat-
ment of hypertension and depression, medication
education has been shown to improve patient com-
pliance with success1. Regarding AED therapy,
previous studies also show that medication educa-
tion could significantly reduce drug-related events,
including misinterpretation of directions, side ef-
fects, and noncompliance2, 3. Although the effect
of medication education on patient compliance and
treatment outcome has been widely recognised, lim-
ited data is available at present concerning what
patients actually know about their AED treatment
regimen4, 5.
The conventional medication education in Taiwan is
mainly verbal. It emphasises the communication be-
tween physician and patient about epilepsy and its
treatment. To patients who still have questions about
AEDs, clinical pharmacist offers counselling. There
are educational pamphlets in the waiting room, but
these only cover general health issues. Up to now, there
is no published data assessing the medication knowl-
edge and compliance of epilepsy patients in Taiwan.
In this study, we conducted a hospital-based survey
in a tertiary care center located in northern Taiwan to
assess the AED knowledge and compliance achieved
by the conventional verbal education. Furthermore,
sources from where patients obtained their AED in-
formation and the impact of written AED information
were examined.
1059–1311/$30.00 © 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
474 L. Liu et al.
Table 1: Questionnaire for epilepsy medication assessment.
1. Do you know the name of your seizure medication?
Please specify.
 Yes  No Name of drug:
2. Do you know what the dose and frequency of your
medication is?
 Yes  No Dose & frequency:
3. Can you name at least one side effect that may occur when
you first taking seizure medication?
 Yes  No Initial side effect:
4. Can you name one side effect of your seizure medication
that could be serious and should inform your physician
immediately?
 Yes  No Serious side effect:
5. Do you have the habit of keeping a seizure diary?
 Yes  No If no, please specify the reason:
6. Do you take the medication according to the physician’s
instruction?
 Yes  No If no, please specify the reason and how often:
MATERIALS AND METHODS
EMA questionnaire
The questionnaire for epilepsy medication assessment
(EMA) was developed and pre-tested on six ambu-
latory patients at Taipei Veterans General Hospital
(Table 1). The EMA consisted of six questions focus-
ing on AED treatment regimen (n = 2), side effects
(n = 2), seizure diary (n = 1), and compliance (n =
1). The number of questions that patient gave correct
or positive answers was taken as the EMA score. Pa-
tients were inquired to specify the sources of their drug
information. The survey period ranged from Septem-
ber 1, 2000 to March 31, 2001.
Patient selection
Patients with epilepsy who had taken AEDs for at
least 1 year and had the ability to comprehend, read,
and write in Chinese were included. These patients
were regularly followed in the epilepsy clinic every
4 weeks. Patient consents were obtained before the
survey began.
AED information leaflets
AED information leaflets were prepared by clinical
pharmacists and revised by neurologists. Each drug
had its own leaflet discussing the indication, adminis-
tration, drug interactions, side effects and therapeutic
indicators. The contents of leaflets fulfill the FDA’s re-
quirements and can be found on the hospital’s website
(http://www.vghtpe.gov.tw/∼pharm/PATIENT SER/
PatientServiceHome.htm)5.
Baseline and follow-up assessments
All qualifying patients were asked to fill out the
questionnaire at the epilepsy clinic. On completion of
the baseline assessment, patients received the AED
information leaflets from the clinical pharmacist. A
follow-up assessment by filling out the same ques-
tionnaire was done on the next 4-week visit.
Serum AED levels
Steady-state drug levels were monitored in the base-
line and compared with the patient-reported compli-
ance. Serum carbamazepine, phenytoin, and valproate
levels were determined by fluorescence polarization
immunoassay (TDxFLx, Abbott Park, IL, USA).
Statistical analysis
Statistical analysis was performed by Pearson
chi-square test and linear regression. A P-value of
less than 0.05 was considered significant.
RESULTS
Sixty-eight patients met the inclusion criteria. Among
them, 51 patients (75.0%) agreed to participate the
survey and their demographics are summarised in
Table 2. During the past 6 months, 30 patients were
seizure free and 18 of them had previously under-
gone epilepsy surgery. Regarding numbers of AEDs,
15 patients (29.4%) were on monotherapy; whereas
21 (41.2%), 13 (25.5%), and 2 (3.9%) patients were
treated with 2, 3, and 4 AEDs, respectively. The
most frequently prescribed drug was carbamazepine
(78.4%), followed by valproate (29.4%), lamotrigine
(29.4%), clobazem (21.6%), topiramate (15.7%), vi-
gabatrin (13.7%), phenytoin (11.8%), and clonazepam
(3.9%). Phenobarbital and primidone were not used.
The majority of patients took the medication twice
daily (82.4%), while the rest of patients were either
on three times daily (15.7%) or once daily (1.9%)
dosing schedule.
Results of the baseline and follow-up assessments
were listed in Table 3. In the baseline assessment, 36
patients (70.6%) correctly listed their AEDs and 43 pa-
tients (84.3%) knew the dosage. However, 28 patients
(54.9%) had no idea about side effects that require im-
mediate medical help, and 20 patients (39.2%) were
not knowledgeable about side effects that could hap-
pen when first taking AEDs. While 74.5% of patients
reported being compliant all the time, 13 patients ad-
mitted that, for once or twice per month, they might
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Table 2: Patient demographics.
Characteristics Number of patients
Age
18–19 2 (3.9%)
20–39 38 (74.5%)
40–59 11 (21.6%)
Gender
Male 29 (56.9%)
Female 22 (43.1%)
Educational level
University (≥16 years) 5 (9.8%)
College (14 years) 8 (15.7%)
High school (12 years) 24 (47.1%)
Junior high school (9 years) 9 (17.7)
Primary school (6 years) 5 (9.8%)
Diagnosis
Partial epilepsy 45 (88.2%)
Generalised epilepsy 6 (11.8%)
Epilepsy surgery
Yes 22 (43.1%)
No 29 (56.9%)
Total seizure numbers in previous 6 months
0 30 (55.8%)
1–2 11 (21.6%)
3–9 5 (9.8%)
≥10 5 (9.8%)
Table 3: Results of epilepsy medication assessment.
Questions in EMA Baseline Follow-up P-value
Correct or positive Incorrect or negative Correct or positive Incorrect or negative
answer answer answer answer
Drug name 36 (70.6%) 15 (29.4%) 45 (88.2%) 6 (11.8%) 0.03
Dosage 43 (84.3%) 8 (15.7%) 45 (88.2%) 6 (11.8%) 0.57
Initial side effect 31 (60.8%) 20 (39.2%) 43 (84.3%) 8 (15.7%) 0.01
Serious side effect 23 (45.1%) 28 (54.9%) 47 (92.7%) 4 (7.8%) <0.01
Epilepsy diary 28 (54.9%) 23 (45.1%) 37 (72.6%) 14 (27.5%) 0.06
Compliance 38 (74.5%) 13 (25.5%) 44 (86.3%) 7 (13.7%) 0.14
EMA: epilepsy medication assessment.
Fig. 1: Medication information sources for patients with epilepsy.
forget to take the medicine. There were 23 patients
(45.1%) who did not regularly keep his/her seizure di-
ary. The averaged EMA score increased from 3.9±1.9
to 5.1± 1.7 after the provision of AED leaflets (P <
0.001). In comparison of the baseline, the awareness
of side effects was significantly improved (P < 0.05).
In this study, 41 patients had their steady-state
AED levels monitored. The drug levels were all
within the therapeutic range and perfectly matched
the self-reported compliance. There were 10 patients
who did not have their AED levels checked. Among
them, 3 patients were on monotherapy with recently
available AED, the rest were on the tapering stage
because of satisfied seizure control.
Fig. 1 shows the sources of medication information
of patients. On average, each patient had 2.8±1.4 dif-
ferent sources of drug information. Physicians were
the main providers for verbal education. Pamphlets
provided in the waiting room were also considered
good references. As illustrated by Fig. 2, the baseline
EMA score positively correlates with the number of
information sources (r = 0.62, P < 0.001). There
were five patients (9.8%) who would search for medi-
cation information from the Internet. All of them were
476 L. Liu et al.
Fig. 2: EMA score at the baseline correlated with the number of medication information sources. The number beside each dot
represents the total number of subjects.
university graduates and their baseline EMA score
(4.8± 0.7) was apparently higher than the rest of pa-
tients (3.8 ± 1.9). Four of these five patients were
seizure free in the previous 6 months.
DISCUSSION
Patient education in epilepsy focuses heavily on
disease knowledge and self-care, but little on med-
ication education6, 7. Goldstein et al. reported that
more than one-quarter of epilepsy patients gave in-
correct information concerning their AED regimens8.
Dawkins et al. also demonstrated that patients had
limited knowledge of AED regimens9. In this study,
the medication knowledge of our patients is similar
to Goldstein’s finding, but better than Dawkins’. The
difference may largely be due to patient sampling.
Dawkins’ patients were identified from general prac-
tices, whereas our study included patients who had
received long-term treatment from epilepsy experts.
In addition, our study population consisted mostly of
patients with good seizure control and who complied
optimally with their AED regimens.
This preliminary study found that the EMA score of
patients raised 30% by the provision of AED leaflets.
Apparently, the written information satisfied the
patient’s intellectual hunger for medication knowl-
edge. However, we cannot exclude the possibility that
patients who agree to participate in a study may be
more motivated to know their medication from the
start. Besides, since the follow-up assessment used
the same questionnaire as the baseline, the results
might be confounded by previous experience. The
interpretation must be conservative given the realities
of this setting.
Patient compliance is a complicated issue in treat-
ment of chronic diseases. Previous studies found that
as many as 30–50% of patients do not consistently
comply with their AED regimens10. Many factors
contribute to noncompliance of AED treatment in
patients with epilepsy, such as lacking of communica-
tion between patient and physician, inadequate medi-
cation knowledge, adverse effects, and poor response,
etc. To optimize patient adherence, physicians in our
epilepsy clinic usually prescribe long-acting prepara-
tions and reduce the number of AEDs whenever pos-
sible. Therefore, our patients seemed to have similar
or even better compliance in comparison with other
studies. Most of our patients used pillboxes and the
steady-state AED levels were within the therapeutic
range. We did not adopt devices such as an electronic
medication events monitoring system to determine
compliance, so it is uncertain whether the patient
took the correct doses at the correct times11. After
provision of AED leaflets, we found an improvement
of AED compliance in the patients, though not sta-
tistically significant. In this study, we did not include
seizure outcome for analysis because more than half of
patients have been seizure free for at least 6 months at
enrollment.
More than 60% of patients considered the pamphlets
provided in the waiting room very helpful, though too
simplified. Owing to the heavy workload in a clinic
setting, patients have to wait for a while before they
could speak to their physicians. We are now up to place
more posters and pamphlets for patients to read while
waiting. Our study also revealed that approximately
10% of patients acquired AED knowledge through the
Internet; most of them were high education level and
had good seizure control. This may predict the gen-
eral trend in the future. Since most drug-associated
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problems occur after patients have left the hospital,
medication education should be provided not only
when the patient is in the hospital, but also at any time
when they need it12. Because of its accessibility to pa-
tients, a medication education website is probably an
ideal place for the medical experts to provide appro-
priate and timely information and for the patients to
exchange their drug experiences13.
CONCLUSION
A lack of AED knowledge results in decreased patient
compliance, which is a serious hindrance to success-
ful treatment and can place the patient at unnecessary
risk. The conventional verbal education in Taiwan
did not cover the drug-related issues sufficiently.
Nonetheless, it achieved patient compliance similar
to that of previous studies. Providing patients with
written medication information can overcome the
shortcomings of verbal education and is an effective
intervention strategy to improve medication knowl-
edge and compliance. Owing to the dynamic nature
of drug information, we strongly suggest health care
professionals to set up medication education websites
and provide patients with up-to-date information.
Further studies are needed to assess clinical outcomes
and investigate the impact of medication education in
ambulatory settings.
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